Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Revenue from operations increased 17.3% year on year to Rs 4,338 crore from Rs 3,697 crore. On a quarter-on-quarter basis, revenue grew 7.6% from Rs 4,031 crore.
Gross profit increased 18.9% year on year to Rs 3,134 crore from Rs 2,635 crore. Gross margin improved 90 basis points to 72.2% from 71.3% a year earlier, although it declined 60 basis points from 72.8% in the previous quarter.
EBITDA rose 27.2% year on year to Rs 1,175 crore from Rs 924 crore. The EBITDA margin expanded 210 basis points to 27.1% from 25% in Q2 FY26. Sequentially, EBITDA increased 10.8% from Rs 1,060 crore, while the margin improved 80 basis points from 26.3%.
Domestic business revenue increased 14.8% year on year to Rs 3,657 crore, accounting for 84% of total revenue. Exports revenue surged 32.7% year on year to Rs 681 crore, accounting for 16% of total revenue.
The company said domestic growth was supported by 1.2 times volume outperformance against the Indian pharmaceutical market. Its chronic business recorded mid-teen growth, led by 19% growth in cardiac products and 16% in diabetes. Acute therapies grew 1.1 times the market, supported by 19% growth in gastroenterology and 26% in vitamins, minerals and nutrition products. The international business grew 33%, while over-the-counter products recorded muted growth during the quarter.
Mankind Pharma also said its acquisition of Armed Cell Therapeutics marked its entry into next-generation CAR-T therapies and strengthened its research and development capabilities.
Mankind Pharma operates in the pharmaceutical formulations and consumer healthcare sectors, with a portfolio spanning acute and chronic therapies, women's health and over-the-counter products. The company has 32 manufacturing facilities and seven research and development centres supported by more than 740 scientists. Its distribution network includes over 18,500 field professionals and reaches more than five lakh doctors across urban and rural India.
Media, realty and pharma shares advanced while private bank and IT stocks declined.
As per provisional closing data, the S&P BSE Sensex declined 8.08 points or 0.01% to 73,598.67. The Nifty 50 index fell 3.45 points or 0.02% to 22,749.75.
The broader market outperformed the frontline indices. The Nifty MidCap 150 Index advanced 1.01% and the Nifty SmallCap 250 Index rose 2.01%.
The market breadth was strong. On the BSE, 2,938 shares rose and 1,381 shares fell. A total of 238 shares were unchanged.
The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, fell 3.67% to 16.53.
Initial Public Offer (IPO):
EAAA India Alternatives received bids for 14,04,675 shares as against 52,99,684 shares on offer, according to stock exchange data at 15:30 IST on 27 October 2026. The issue was subscribed 0.27 times.
The issue opened for bidding on 26 October 2026 and will close on 28 October 2026. The price band of the IPO is fixed between Rs 1,585 and 1,665 per share. An investor can bid for a minimum of 9 equity shares and multiples thereof.
BLS Polymers received bids for 9,87,45,600 shares as against 1,19,00,000 shares on offer, according to stock exchange data at 15:30 IST on 27 October 2026. The issue was subscribed 8.30 times.
The issue opened for bidding on 27 October 2026 and will close on 29 October 2026. The price band of the IPO is fixed between Rs 142 and 150 per share. An investor can bid for a minimum of 100 equity shares and multiples thereof.
SFC Environmental Technologies received bids for 11,71,710 shares as against 1,41,59,744 shares on offer, according to stock exchange data at 15:30 IST on 27 October 2026. The issue was subscribed 0.08 times.
The issue opened for bidding on 27 October 2026 and will close on 29 October 2026. The price band of the IPO is fixed between Rs 313 and 330 per share. An investor can bid for a minimum of 45 equity shares and multiples thereof.
Buzzing Index;
The Nifty Media index jumped 3.49% to 1,621.70. The index declined 5.47% in the past five trading sessions.
Sun TV Network (up 10.94%), Prime Focus (up 9.22%), Saregama India (up 4.31%), PVR Inox (up 4.22%) and Tips Music (up 3.47%), Network 18 Media & Investments (up 2.85%), D B Corp (up 1.06%), Nazara Technologies (up 0.56%), Zee Entertainment Enterprises (up 0.26%) surged.
Stocks in Spotlight:
Mankind Pharma jumped 8.63% after reporting strong financial results for Q2 FY27, with revenue, EBITDA and net profit increasing year on year. The company's profit after tax rose 37.7% year on year to Rs 716 crore from Rs 520 crore. Sequentially, net profit increased 24.7% from Rs 574 crore in Q1 FY27. Revenue from operations increased 17.3% year on year to Rs 4,338 crore from Rs 3,697 crore. On a quarter-on-quarter basis, revenue grew 7.6% from Rs 4,031 crore.
OneSource Specialty Pharma surged 13.64% after the company reported strong Q2 FY27 results, with revenue and adjusted net profit increasing year on year. The company's adjusted net profit rose 108.69% year on year to Rs 93.7 crore from Rs 44.9 crore in Q2 FY26. Sequentially, adjusted net profit increased 47.25% from Rs 63.7 crore in Q1 FY27. Revenue from operations increased 37.39% year on year to Rs 516.24 crore from Rs 375.76 crore. On a quarter-on-quarter basis, revenue rose 14.97% from Rs 449.02 crore in Q1 FY27.
Aequs tumbled 9.85% after the company’s consolidated net loss widened to Rs 52.39 crore in Q2 FY27 compared with net loss of Rs 20.59 crore in Q2 FY26. Revenue from operations soared 45.27% year-on-year (YoY) to Rs 409.07 crore in Q2 FY27, supported by growth across its aerospace and consumer businesses.
Cipla fell 0.22% after the drug major's consolidated profit attributable to shareholders stood at Rs 878 crore in Q2 FY27, down 35% year on year from Rs 1,351 crore in Q2 FY26. Revenue from operations declined 2.44% year on year to Rs 7,404 crore from Rs 7,589 crore.
Global Market:
Dow futures rose 82 points, signalling a higher opening for US stocks.
European indices declined on Tuesday as investors assessed geopolitical tensions in the Middle East, elevated crude oil prices and the outlook for global interest rates. Caution also prevailed ahead of major US technology earnings and key central bank policy decisions.
Asian equities ended mixed on Tuesday, as the filing for artificial intelligence (AI) company Anthropic's planned initial public offering revived appetite for technology stocks ahead of a busy week of corporate earnings and central bank decisions.
South Korea's economy grew 3.4% year on year in the third quarter of 2026, slowing from 3.7% in the previous quarter, preliminary data from the Bank of Korea showed on Tuesday. GDP expanded 1.0% quarter on quarter, accelerating from 0.6% in the April-June quarter. Semiconductor exports and investment in production equipment supported the expansion, although private consumption fell 0.2% quarter on quarter.
Wall Street ended higher on Monday, 26 October 2026. The Dow Jones Industrial Average rose 146.42 points, or 0.28%, to 52,361.58. The S&P 500 gained 53.09 points, or 0.70%, to 7,676.77, while the Nasdaq Composite advanced 214.04 points, or 0.83%, to 26,169.38. The Philadelphia Semiconductor Index climbed 2.8%, marking its biggest one-day gain in a month, as chip-related shares led the recovery. The technology sector gained 1.5%, leading the S&P 500's 11 major sectors.
Anthropic's IPO filing helped revive the AI trade by highlighting rapid revenue growth alongside the substantial costs and risks of developing advanced AI systems. The company's first-half 2026 net loss widened to $80.7 billion, largely because of a non-operating accounting item related to convertible bonds. Its operating loss narrowed to $693 million, while adjusted operating income turned positive at $1.62 billion, compared with a loss of $1.85 billion a year earlier. Revenue grew 1,368% year on year in the three months ended 30 June 2026. The filing also highlighted risks linked to infrastructure costs, cloud-provider dependence and AI safety.
Individual stocks reflected renewed interest in AI infrastructure. Lumentum gained about 8% and Coherent rose around 6%, while Tesla advanced 5.2% after a Barclays upgrade. Meta Platforms fell 1.9% after announcing plans to raise up to $95 billion through equity offerings to fund its AI infrastructure expansion. The fundraising includes about $35 billion in public offerings and a separate share-sale programme of up to $60 billion. Meta's plans underscore investor scrutiny of the financing required to sustain AI-related capital expenditure.
Economic data offered a mixed signal on US activity and price pressures. The Dallas Federal Reserve's general business activity index rose to 13.4 in October from 9.8 in September, exceeding the 8.8 consensus forecast. However, the production index fell to 15.8 from 29.5, and the new-orders index declined to 9.3 from 30.7. The survey also showed the raw-materials price index rising to 55.3 from 52.2, pointing to continued input-cost pressure.
Mankind Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 2439, up 6.01% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.29% on the day, quoting at 23413.6. The Sensex is at 74819.64, up 0.71%. Mankind Pharma Ltd has risen around 2.72% in last one month.
Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has risen around 2.67% in last one month and is currently quoting at 26710.1, up 1.25% on the day. The volume in the stock stood at 10.39 lakh shares today, compared to the daily average of 3.26 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 2443, up 5.42% on the day. Mankind Pharma Ltd is down 6.01% in last one year as compared to a 7.1% drop in NIFTY and a 20.91% drop in the Nifty Pharma index.
The PE of the stock is 42.34 based on TTM earnings ending June 26.
Mankind Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 2280.2, down 1.25% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 23541.1. The Sensex is at 75140.89, down 0.58%.Mankind Pharma Ltd has eased around 6.47% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has increased around 0.92% in last one month and is currently quoting at 26880.8, down 0.59% on the day. The volume in the stock stood at 1.21 lakh shares today, compared to the daily average of 3.25 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 2293.5, down 0.73% on the day. Mankind Pharma Ltd tumbled 12.59% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.
The PE of the stock is 42.12 based on TTM earnings ending June 26.
Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., China, for the commercialisation of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India.
Commenting on the partnership, Atish Majumdar, Senior President – Sales and Marketing, Mankind Pharma said, “China is rapidly emerging as a hub for innovative biopharmaceutical assets. Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China. This partnership reinforces our commitment to expanding access to advanced therapies for patients in India while further strengthening our presence in the injectable diabetes segment.”
Domestic revenue (ex-Consumer Health) increased 11.0% YoY to Rs 3,180 crore, driven primarily by double digit growth in Mankind business and supported by strong growth in BSV specialty business.
The Consumer Healthcare Business has recorded revenue of Rs 246 crore (up 4% YoY), partly impacted by base effect of discontinued cash and carry business.
Revenue from International business increased by 29% YoY to Rs 605 crore in Q1FY27.
EBITDA improved by 24.7% YoY to Rs 1,060 crore while EBITDA margin expanded 250 basis points YoY to 26.3%
Profit before tax in Q1 FY27 stood at Rs 769 crore, up by 42% from Rs 540 crore in Q1 FY26.
'Our disciplined execution and strengthening business fundamentals, resulted in improvements across key operating and financial metrics in Q1FY27, laying the foundation to deliver long-term sustainable growth,' Mankind Pharma said in a statement.
In a seperate filing, Mankind Pharma informed that its board has approved the issuance of a corporate guarantee aggregating to Rs 150 crore in favour of various banks to secure the various types of credit facilities availed or proposed to be availed by the Bharat Serums and Vaccines (BSV) is a wholly owned subsidiary of the company.
The corporate guarantee will be treated as a contingent liability and commitment for the company to the extent of facility to be availed by the BSV.
Mankind Pharma is one of the largest pharmaceutical company in India. The company operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors.
The scrip shed 0.60% to end at Rs 2576.95 on the BSE today.